The Life Sciences team advised AbSci on its acquisition of Denovium, Inc.
AbSci is a leading synthetic biology company enabling drug discovery and biomanufacturing of next-generation biotherapeutics.
Denovium is an artificial intelligence company pioneering novel AI methods to accelerate innovation in biopharma.
AbSci will integrate the Denovium Engine into its drug discovery and manufacturing cell line development capabilities and expects to realize near term synergies using AI deep learning to better predict relevant variants and cell line characteristics for each new project. With continued application and further training of the Denovium Engine, AbSci’s vision is to make in silico biologic drug discovery and cell line development a reality. This will enable next-generation therapies to make it to market at unprecedented speeds.For more details, read the press release and articles in Endpoints, GeekWire, and Portland Business Journal.